Last week, Numinus Wellness Inc. (TSXV: NUMI) reported a major development and we want to issue an update on the opportunity following this announcement.
The company is focused on creating an ecosystem of health solutions that are centered around the development of evidence-based psychedelic-assisted psychotherapies. Last week, Numinus announced that its MDMA compassionate access trial achieved significant progress toward treating patients with post-traumatic stress disorder (PTSD).
This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), the leading developer of the treatment protocols, research and MDMA-assisted therapy training programs. Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful use of psychedelics and cannabis.
When it comes to strategic relationships, we believe that MAPS represents one of the best potential partners and will monitor how the trial advances from here. Going forward, the companies will work to provide people who suffer from PTSD with more treatment options and we are favorable on this initiative.
This first-of-its-kind trial in Canada has successfully transitioned into the pre-implementation stage at Numinus’ Vancouver clinic. This follows the successful completion of several milestones and we are favorable on the track record of execution that Numinus is creating for itself. The company will be responsible for collecting safety data for Health Canada to further implement key research that supports individuals who are living with PTSD and have not benefited from existing treatment options.
A draft MDMA-assisted therapy protocol for PTSD has been adapted for the trial and it includes clear guidance surrounding necessary screening processes, patient health histories, as well as indications and potential contraindications before accepting participants. Initial regulatory meetings with Health Canada to define the trial’s implementation science strategy is complete and the next steps will include obtaining ethical and Health Canada approvals to allow for the recruitment of participants according to COVID-19 public health protocols.
During the last quarter, Numinus has been a strong performer and we will continue to monitor the opportunity. If you are interested in learning more about Numinus and MAPS, please send an email to firstname.lastname@example.org with the subject “Numinus and MAPS” to be added to our distribution list.